Results from the ODYSSEY trial will be presented at this year’s Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, USA.
The trial team’s abstract titled “Adequate dolutegravir exposure dosed bid with rifampicin in children 6 to <18 years” has been accepted for a poster presentation and a themed discussion.
Data from the pharmacokinetic sub-study within the ODYSSEY trial among 17 children with TB/HIV co-infection will inform future use of dolutegravir in combination with rifampicin-based TB treatment in the paediatric population.
The poster will be introduced during the themed discussion “Novel approaches to study pediatric antiretroviral dosing and safety – td-09” that will be held from on Tuesday 10 March at 13:30 – 14:30 (EST). The poster presentation follows shortly after this at 14:30 – 16:00 (EST) during poster session “Novel approaches to pediatric antiretroviral dosing and safety – p-p08”. Both the poster and the themed discussion will be delivered on behalf of the ODYSSEY trial group by Hylke Waalewijn, PhD student and pharmacologist from Prof. David Burger’s research group based at The Radboud Institute of Health Sciences in Nijmegen, The Netherlands.
CROI brings together basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases.
